1,143 results on '"Levesque, Mitchell"'
Search Results
2. Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition
3. The genetic evolution of acral melanoma
4. Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA
5. Size-exclusion chromatography combined with DIA-MS enables deep proteome profiling of extracellular vesicles from melanoma plasma and serum
6. MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides
7. INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas
8. Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance
9. Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma
10. Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients
11. Androgen receptor is a determinant of melanoma targeted drug resistance
12. Dynamic thresholding and tissue dissociation optimization for CITE-seq identifies differential surface protein abundance in metastatic melanoma
13. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
14. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
15. Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID‐19 patients
16. Radial matrix constraint influences tissue contraction and promotes maturation of bi-layered skin equivalents
17. Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening?
18. Phase-specific signatures of wound fibroblasts and matrix patterns define cancer-associated fibroblast subtypes
19. The p300/CBP Inhibitor A485 Normalizes Psoriatic Fibroblast Gene Expression In Vitro and Reduces Psoriasis-Like Skin Inflammation In Vivo
20. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
21. OS-086-YI Protein tyrosine phosphatase non-receptor type 2 controls hepatic function of cytotoxic T cells in metabolic dysfunction-associated steatohepatitis
22. Defining the Molecular Landscape of Cancer-Associated Stroma in Cutaneous Squamous Cell Carcinoma
23. Mediators of Capillary-to-Venule Conversion in the Chronic Inflammatory Skin Disease Psoriasis
24. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
25. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice.
26. STK11 Prevents Invasion through Signal Transducer and Activator of Transcription 3/5 and FAK Repression in Cutaneous Melanoma
27. Live slow-frozen human tumor tissues viable for 2D, 3D, ex vivo cultures and single-cell RNAseq
28. Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism
29. Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread.
30. Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
31. CD112 Supports Lymphatic Migration of Human Dermal Dendritic Cells
32. Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland
33. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma
34. Data from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
35. Supplementary Fig. S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
36. Supplementary Table S1 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
37. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
38. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
39. Identification of bacteria-derived HLA-bound peptides in melanoma
40. Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition
41. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
42. Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma
43. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma
44. Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
45. LKB1‐SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition
46. Single-cell spatial proteomics identifies the JAK/STAT pathway as an actionable therapeutic target in lethal cutaneous drug reactions
47. The genetic evolution of acral melanoma
48. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
49. Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4
50. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.